[go: up one dir, main page]

MX2009008825A - Nuevos metodos de terapia anticolinergica. - Google Patents

Nuevos metodos de terapia anticolinergica.

Info

Publication number
MX2009008825A
MX2009008825A MX2009008825A MX2009008825A MX2009008825A MX 2009008825 A MX2009008825 A MX 2009008825A MX 2009008825 A MX2009008825 A MX 2009008825A MX 2009008825 A MX2009008825 A MX 2009008825A MX 2009008825 A MX2009008825 A MX 2009008825A
Authority
MX
Mexico
Prior art keywords
patient
novel methods
treatment
aclidinium
administering
Prior art date
Application number
MX2009008825A
Other languages
English (en)
Inventor
Jorge Beleta Supervia
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39247776&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009008825(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of MX2009008825A publication Critical patent/MX2009008825A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención proporciona métodos para el tratamiento por inhalación de una enfermedad o estado respiratorio en un paciente que necesite el tratamiento sin producir en el paciente efectos antimuscarínicos sistémicos, comprendiendo administrar al paciente una cantidad eficaz de aclidinio.
MX2009008825A 2007-02-21 2008-01-31 Nuevos metodos de terapia anticolinergica. MX2009008825A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90284307P 2007-02-21 2007-02-21
PCT/EP2008/000782 WO2008101591A1 (en) 2007-02-21 2008-01-31 Novel methods

Publications (1)

Publication Number Publication Date
MX2009008825A true MX2009008825A (es) 2009-10-12

Family

ID=39247776

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009008825A MX2009008825A (es) 2007-02-21 2008-01-31 Nuevos metodos de terapia anticolinergica.

Country Status (31)

Country Link
US (2) US20110243924A1 (es)
EP (1) EP2120936B1 (es)
JP (2) JP5739616B2 (es)
KR (2) KR20090114401A (es)
CN (2) CN105395548A (es)
AR (1) AR065392A1 (es)
AT (1) ATE513547T1 (es)
AU (1) AU2008217301B2 (es)
BR (1) BRPI0806392A8 (es)
CA (1) CA2678975C (es)
CL (1) CL2008000461A1 (es)
CO (1) CO6210814A2 (es)
CY (1) CY1111799T1 (es)
DK (1) DK2120936T3 (es)
EC (1) ECSP099556A (es)
ES (1) ES2367722T3 (es)
HR (1) HRP20110556T1 (es)
IL (1) IL200278A (es)
MX (1) MX2009008825A (es)
MY (1) MY153408A (es)
NZ (1) NZ578473A (es)
PE (1) PE20081789A1 (es)
PL (1) PL2120936T3 (es)
PT (1) PT2120936E (es)
RU (1) RU2484821C2 (es)
SI (1) SI2120936T1 (es)
TW (1) TWI475994B (es)
UA (1) UA98136C2 (es)
UY (1) UY30901A (es)
WO (1) WO2008101591A1 (es)
ZA (1) ZA200904941B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
CA2931876A1 (en) 2009-08-07 2011-02-10 Generics [Uk] Limited Anhydrate of tiotropium bromide
WO2011095800A2 (en) * 2010-02-02 2011-08-11 Generics [Uk] Limited Analytical methods
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
US20150202297A1 (en) * 2012-07-05 2015-07-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US20200054611A1 (en) 2017-01-09 2020-02-20 Gt Biopharma, Inc. Use and composition for treating myasthenia gravis and other myasthenic syndromes
WO2019023318A1 (en) 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS USING PYRIDOSTIGMINE AND AN ANTAGONIST OF NK-1 FOR TREATING SEVERE MYASTHENIA
WO2019023175A1 (en) * 2017-07-25 2019-01-31 Gt Biopharma, Inc. PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE AND NEOSTIGMINE AND AN ANTAGONIST NK-1 FOR THE TREATMENT OF SEVERE MYASTHENIA
WO2020014072A1 (en) * 2018-07-09 2020-01-16 Gt Biopharma, Inc. Neostigmine pharmaceutical combination for treating myasthenia gravis
KR102169476B1 (ko) * 2020-05-20 2020-10-23 (주)신테카바이오 제2형 중증급성호흡기증후군 코로나바이러스 감염 질환의 예방 또는 치료용 조성물
CN113825508A (zh) 2020-05-20 2021-12-21 新泰克生物技术有限公司 用于预防或治疗严重急性呼吸综合征冠状病毒2感染疾病的组合物
EP4469041A4 (en) * 2022-01-28 2026-01-07 Univ Of Montreal ANTICHOLINERGIC COMPOUNDS INTENDED FOR USE IN THE TREATMENT OF NEUROMUSCULAR DISORDERS
CN115267024B (zh) * 2022-07-31 2023-06-30 浙江知一药业有限责任公司 治疗呼吸系统疾病的药物组合物及其检测方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US20050026948A1 (en) * 2003-07-29 2005-02-03 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising an anticholinergic and a betamimetic
DE102004016179A1 (de) 2004-03-30 2005-10-20 Boehringer Ingelheim Pharma Verbindungen zur Behandlung von proliferativen Prozessen
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.

Also Published As

Publication number Publication date
CN101616670A (zh) 2009-12-30
CO6210814A2 (es) 2010-10-20
TWI475994B (zh) 2015-03-11
ATE513547T1 (de) 2011-07-15
KR20090114401A (ko) 2009-11-03
UA98136C2 (ru) 2012-04-25
KR20150038750A (ko) 2015-04-08
US20150093374A1 (en) 2015-04-02
JP5739616B2 (ja) 2015-06-24
CY1111799T1 (el) 2015-10-07
RU2009135078A (ru) 2011-03-27
IL200278A0 (en) 2010-04-29
CA2678975A1 (en) 2008-08-28
BRPI0806392A2 (pt) 2011-09-06
PL2120936T3 (pl) 2011-11-30
JP2014062114A (ja) 2014-04-10
MY153408A (en) 2015-02-13
TW200838520A (en) 2008-10-01
IL200278A (en) 2015-03-31
PE20081789A1 (es) 2008-12-27
HK1132673A1 (en) 2010-03-05
ES2367722T3 (es) 2011-11-08
UY30901A (es) 2009-11-10
BRPI0806392A8 (pt) 2019-10-01
PT2120936E (pt) 2011-09-06
ZA200904941B (en) 2011-11-30
JP2010519261A (ja) 2010-06-03
WO2008101591A1 (en) 2008-08-28
CN105395548A (zh) 2016-03-16
HRP20110556T1 (hr) 2011-09-30
AU2008217301B2 (en) 2012-10-04
CA2678975C (en) 2016-11-08
EP2120936A1 (en) 2009-11-25
AR065392A1 (es) 2009-06-03
EP2120936B1 (en) 2011-06-22
DK2120936T3 (da) 2011-09-26
US20110243924A1 (en) 2011-10-06
RU2484821C2 (ru) 2013-06-20
AU2008217301A1 (en) 2008-08-28
ECSP099556A (es) 2009-09-29
NZ578473A (en) 2011-10-28
SI2120936T1 (sl) 2011-10-28
CL2008000461A1 (es) 2008-08-29

Similar Documents

Publication Publication Date Title
MY153408A (en) Novel methods
IL201479A (en) Use of tapentadol for the preparation of pain medication
WO2009008001A3 (en) Inhalation device
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
MX340822B (es) Formulaciones para suministro oral de adsorbentes en el intestino.
MX2010002498A (es) Metodos para tratar o prevenir la infeccion del tracto respiratorio que comprende la administracion de colecalciferol.
IL180565A0 (en) An improved stopcock for administering medicaments into the patient's body
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MY153062A (en) Methods of treating gastrointestinal disorders independent of the intake of food
PH12015500407B1 (en) Methods of treating hypertriglyceridemia
MX2010005631A (es) Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades.
MX2007008379A (es) Metodos y composiciones para minimizar la acumulacion de insulina inhlable en los pulmones.
IN2015DN03219A (es)
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
MY146362A (en) Use of tiotropium salts in the treatment of moderate persistent asthma
WO2011075611A8 (en) Compositions and methods for non-invasive treatment of chronic complications of diabetes
WO2007135123A3 (en) Mirtazapine for the treatment of neuropathic pain
AR048460A1 (es) Tratamiento de la funcion respiratoria alterada con gaboxadol
TW200738229A (en) Memantine for the normalization of visual acuity deficits
TH0801000702A (th) อะคลิดิเนียมสำหรับใช้โดยการสูดในการบำบัดโรคทางเดินหายใจ
UA34817U (ru) Способ медицинской реабилитации больных с синдромом повышенной усталости на фоне хронического тонзиллита
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
UA35600U (ru) Способ лечения хронического обструктивного заболевания легких

Legal Events

Date Code Title Description
FG Grant or registration